The FDA has approved GlaxoSmithKline  (GSK)’s belantamab mafodotin for relapsed or refractory multiple myeloma. The antibody–drug conjugate (ADC) is the first therapeutic from the crowded  BCMA-targeted pipeline to secure approval.

Click here to original publication.
Fonte: Nature Reviews | Drug Discovery  volume 19 | OCTOBER 2020 | 659